Business
Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs
ORION CORPORATION PRESS RELEASE12 MAY 2026 at 10:30 EEST Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs Orion Corporation today announced that on 6 May 2026 the U.S. Food and Drug Administration (FDA) has approved Tessie® (tasipimidine) oral solution for dogs. Tessie® is indicated for the treatment of noise aversion and separation anxiety in dogs. Tasipimidine is an Orion proprietary molecul
About this update from Orion Oyj Class A
[{"type":"image","alt":"Orion Oyj","displaySize":"","headline":null,"caption":"Orion Oyj","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":118,"url":"https://media.zenfs.com/en/globenewswire.com/81ce103a881cae9326d4e01207e6d4b0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oGQKPK6RsO5eTABx1IN6xw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NQ--/https://media.zenfs.com/en/globenewswire.com/81ce103a881cae9326d4e01207e6d4b0","width":300,"height":118},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/oGQKPK6RsO5eTABx1IN6xw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NQ--/https://media.zenfs.com/en/globenewswire.com/81ce103a881cae9326d4e01207e6d4b0","width":300,"height":118}},"lazy":false},{"type":"text","content":"ORION CORPORATION PRESS RELEASE12 MAY 2026 at 10:30 EEST","length":60,"tagName":"p"},{"type":"text","content":"Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs","length":152,"tagName":"p"},{"type":"text","content":"Orion Corporation today announced that on 6 May 2026 the U.S. Food and Drug Administration (FDA) has approved Tessie® (tasipimidine) oral solution for dogs.","length":156,"tagName":"p"},{"type":"text","content":"Tessie® is indicated for the treatment of noise aversion and separation anxiety in dogs.","length":88,"tagName":"p"},{"type":"text","content":"Tasipimidine is an Orion proprietary molecule and a new active substance for veterinary use in the U.S. It acts in the central nervous system by blocking the startle reflex and thus counteracting arousal.","length":204,"tagName":"p"},{"type":"text","content":"“This approval adds to Orion Animal Health’s portfolio of veterinary medicines developed to address clearly identified clinical needs,” says Niclas Lindstedt, Executive Vice President, Orion Animal Health. “Our long-standing approach to innovation is centered on applying scientific expertise to create treatment options that support veterinary decision-making and animal welfare.”","length":381,"tagName":"p"},{"type":"text","content":"Orion’s long-standing strategic partner, Zoetis, has the exclusive right to market and sell Tessie® in the United States. Tessie® is anticipated to be available in the U.S. by mid-2027 and will expand Zoetis' behavioral product portfolio, alongside Sileo® and Bonqat®....